Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November.
The drug’s manufacturer, Novartis, said Sept. 29 it plans to launch a direct-to-patient platform on Nov. 1 for cash-paying U.S. patients. For a four-week supply, Cosentyx’s list price is $7,936 for a self-injection package and $4,401 per intravenous infusion, according to Novartis.
Cosentyx (secukinumab) is an FDA-approved biologic to treat six immune-mediated inflammatory diseases, including plaque psoriasis and psoriatic arthritis.
In 2024, hospitals, clinics, pharmacies and other healthcare facilities spent $7.7 billion on the medication, making it the 16th most expensive drug in healthcare.
Several other drugmakers have recently launched direct-to-consumer portals and other platforms that offer discounts to cash-paying patients, including Pfizer, Eli Lilly and Novo Nordisk.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.